(3.236.100.86) 您好!臺灣時間:2021/05/06 15:40
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:林倩伶
研究生(外文):Chien-Ling Lin
論文名稱:探討淋巴細胞次群分佈及活化在台灣健康男女性、口腔癌前病變病人及口腔癌病人之差異以及相關影響因子之研究
論文名稱(外文):Analysis of different lymphocyte subsets and activation on healthy people, patient with precancerous lesion and oral cancer in Taiwan
指導教授:鄭景暉鄭景暉引用關係郭英雄郭英雄引用關係
指導教授(外文):JH JengYS Kuo
學位類別:碩士
校院名稱:國立臺灣大學
系所名稱:臨床牙醫學研究所
學門:醫藥衛生學門
學類:牙醫學類
論文種類:學術論文
論文出版年:2004
畢業學年度:92
語文別:中文
論文頁數:119
中文關鍵詞:淋巴細胞口腔癌
外文關鍵詞:oral cancerlymphocyte
相關次數:
  • 被引用被引用:0
  • 點閱點閱:172
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
本文利用流式細胞儀檢測台灣地區健康男女性(男80位、女50人)、口腔癌前病變病患(28位)及口腔癌病人(87位)的淋巴細胞次群(CD4/CD3-T細胞、CD8/CD3-T細胞、CD19-B細胞、CD56-NK細胞)及淋巴細胞活化(CD69、CD25)分佈。抽取受檢者周邊血液2 ml,經過檢測之後有三個主要的發現,一、淋巴細胞次群和活化的分佈會受到性別、年齡、種族不同而分佈有所差異。女性在CD4/CD3-T細胞比例比男性來得多。年齡大於60歲的男性,其CD8/CD3-T細胞、CD56-NK細胞比例比其他年齡層的男性來得高。而年齡小於30歲的男性在淋巴細胞CD8/CD69、CD8/CD25活化比例明顯高於其他年齡層的男性。二、淋巴細胞次群和活化的分佈是隨著疾病的進展不同而改變,結果發現,男性癌症病人的NK細胞、CD4/CD69、CD19/CD69和CD56/69淋巴活性比男性健康人來的高,B細胞和CD19/CD25淋巴活性比例比健康者來得低。口腔癌前病變的男性病人的NK細胞、CD4/CD3-T細胞及B細胞比例則比男性健康者來得高,另外口腔癌男性病人的B細胞則比口腔癌前男性病人來得低,但在淋巴細胞活化CD4/CD69的比例則是比較高。在女性癌症病人方面,結果類似男性病患,其NK細胞和CD4/CD69淋巴細胞活化比例皆高於健康女性。三、收集癌症男性病患臨床資料加以分析,包括腫瘤部位、臨床TNM stage、病理組織分類、病患嚼食檳榔、抽菸、喝酒習慣、系統性疾病及是否為首次得到等因素加以討論。我們發現影響口腔癌患者免疫細胞分佈不同的主因,乃為有無遠處轉移及是否為首次得到或是復發性癌症等原因,由統計結果發現,復發性病人的淋巴細胞CD56/CD69活化比例明顯比首次得到來得高,而到了重度癌症末期,癌症病人體內的免疫細胞分佈上明顯的改變,體內的CD4/CD3-T細胞比例明顯減少、CD8/CD3-T細胞比例增加,幾乎所有的淋巴細胞活活化比例皆增加。簡單來說,由資料結果顯示免疫系統會因為疾病的發展,而有所改變。最後我們依據上述的統計資料,寫出口腔癌、頸部淋巴轉移及是否為復發性癌症的預測方程式。
The lymphocyte subsets (CD4/CD3-T cell, CD8/CD3-T cell, CD19-B cell, CD56-NK cell) and lymphocyte activation antigen ( CD69, CD25) in the peripheral blood (2 ml) of healthy men and women in Taiwan (male: 80, female:50), per cancerous people (28 patients) and oral cancer people ( male: 87, female : 10) were analyzed using two-color flow cytometry. The data were analysised and the three main results were found. First, the sex, age, race can influence the distribution of lymphocyte subsets and activation. The distribution of CD4/CD3-T cell in women was higher than men. If men were older than 60 years of age, the increased proportion of CD8/CD3-T cell and NK cell were than others. If men were younger than 30 years of age, the increased proportion of activation CD8/CD69 and CD8/CD25. Second, the distribution of lymphocyte subsets and activation were change with process of disease. The results showed that the distribution of NK cell, CD4/CD69, CD19/CD69 and CD56/CD69 in men with oral cancer were increased siginificantly in healthy men, and decreased expression of B cell and CD19/CD25 was noted compared with B cell and CD19/CD25 in healthy men. The increased expression NK cell and B cell in men with precancerous lesion was than healthly men. The distribution of NK cell in women with oral cancer was increased than healthy women. Third, we collect all data of patients including diagnosis, TMN stage, pathologic report, fresh or recurrent cancer, systemic disease, habit of chewing betel quids, smoking and drinking. These data were analysised, and we found that habit, pathologic status, tumor location, tumor size and systemic disease were not the major influenced factor. We found that organ metastasis and recurrent were the major influenced factor. The expression of activation in CD56/CD69 in men with recurrent oral cancer was increased than men with fresh cancer. The lymphocyte subsets and activation expression of advanced-terminal oral cancer patient were siginificantly change. Final, we make the prediction program for oral cancer according to data.
導論……………………………………………………….p3-p12
研究目的………………………………………………….p13
方法及步驟……………………………………………….p14-20
結果……………………………………………………….p21-42
討論……………………………………………………….p43-63
結論……………………………………………………….p64-67
參考文獻………………………………………………….p68-76
表格……………………………………………………….p77-113 圖………………………….…………………………..….p114-119
1. Asseman C, Herrath M. About CD4pos CD25pos regulatory cells. Autoimmun Rev, 2002, 1(4): 190-197. 2. Baecher-Allan C, Viglietta V, Hafler DA. Inhibition of human CD4(+)CD25(+high) regulatory T cell function. J Immunol. 2002, 169(11): 6210-6217. 3. Barbieri C, Fujisawa M M, Yasuda CL, Metze I L, Oliverira E C, Santos L M B, Lopes L R, Andreollo N A. Effect of surgical treatment on the cellular immune response of gastric cancer patients. Brazilian Journal of Medical and Biological Research, 2003, 36:339-345.
4. Bisset LR, Lung TL, Kaelin M, Ludwig E, Dubs RW. Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur J Haematol. 2004, 72:203-212. 5. Bofill M, Janossy G, Lee CA, MacDonald-Burns D, Phillips AN, Sabin C, Timms A, Johnson MA, Kernoff PB. Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol, 1992, 88:243-252. 6. Borrego F, Robertson M J, Ritz J, Pena J, Solana R. CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology. 1997, 97:159-165.
7. Boon Thierry, Old Lloyd J. Cancer tumor antigen. Current Opinion in Immunology. 1997, 9:681-683.
8. Chen CH, Kuo C, Pan CC, Chou MY. Risk of oral cacner associated with human papillomavirus infection, betel quid chewing, and cigarette smoking in Taiwan – an integrated molecular and epidemiological study of 58 cases. J Oral Pathol Med, 2002, 31:317-322.
9. Chen Chun-Kai, Wu Ming-Yih, Chao Kuang-Han, Ho Hong-Nerng, Sheu Bor-Ching, Huang Su-Cheng. T lymphocyte and cytokine production in ascitic fluid of ovarian Malignancies J Formos Med Assoc. 1999, 98:24-30.
10. Chiang CP, Wu HY, Liu BY. Quantitative analysis of immunocompetent cells in oral submucous fibrosis in Taiwan. Oral Oncol, 2002, 38:56-63.
11. Chiu CJ, Chang ML, Chang CP. Interaction of collagen-related genes and susceptibility to betel quid- induced oral submucous fibrosis. Cancer Epidemiol Biomarkers Prevention, 2002, 11: 646-653.
12. Choong M L, Ton S H, Cheong S K. Influence of race, age and sex on the lymphocyte subsets in peripheral blood of healthy Malaysian adults. Ann ClinBiochem, 1995, 32:532-539.
13. Ciriaco A, Piccirillo, Ethan M. Shevach. Cutting edge: Control of CD8+ T cell activation by CD4+ CD25+ immunoregulatory cells. J. Immunol. 2001, 167:1137-1140. 14. Cooper Megan A, Fehniger Todd A, Caligiuri Michael A. The biology of human natural killer-cell subsets. Trends in Immunology, 2001, 22(11): 633-640.
15. Cornfield Dennis, Liu Zach, Gorczyca Wojciech, Weiberger James. The potential role of flow cytometry in the diagnosis of small cell carcinoma. Arch Pathol Lab Med. 2003, 127:461-464.
16. Dammer R, Wurme E M, Niederdellmann H, Fleischmann H, Knuchel R. Innunocytochemical venous blood studies in patients with manifest oral cavity carcinomas, oral precancerous conditions, benign tumors and in chronic alcoholic patients. Mund Kiefer Gesichtschir. 1997, 1(2): 95-103.
17. Desai SS, Ghaisas SD, Jakhi SV. Cytogenetic damage in exfoliated oral mucosal cells and circulating lymphocytes of patients suffering from precancerous oral lesions. Cancer Lett, 1996, 109:9-14.
18. Dietz A, Heimlich F, Daniel V, Polarz H, Weidauer H, Maier H. Immunomodulating effects of surgical intervention in tumors of the head and neck. Otolaryngol Head Neck Surg. 2000, 123(1 Pt 1): 132-139.
19. Dubois B, Chapat L, Goubier A, Kaiserlian D. CD4+CD25+ T cells as key regulators of immune responses. Eur J Dermatol. 2003, Mar-Apr; 13(2): 111-116.
20. Erik H, Schepman Kees-Pieter, Isaac. The possible premalignant character of oral lichen planus and oral lichenoid lesions: A prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003, 96:164-171.
21. Ershler William B. The influence of an aging immune system on cancer incidence and progression. Journal of Gerontology. 1993, 48(1): B3-B7.
22. Flow cytometry. Oregon Medical Laboratories. 2003, http://www.omlabs.com.
23. Gallimore A, Sakaguchi S. Regulation of tumour immunity by CD25+ T cells. Immunology. 2002, 107(1): 5-9. 24. Gavioli Riccardo, Risso Angela, Smilovich Daniela, Baldissarro Isabella, Capra M. Cristina, Bargellesi Antonio, Cosulich M. Elisabetta. CD69 molecule in human neutrophils: its expression and role in signal-transducing mechanisms. Cellular Immunology. 1992, 142:186-196.
25. Gez E, Mekori T, Struminger L, Rubinov R, Nativ O, Stein A, Haim N, Kuten A. T-cell subpopulation in patients with metastatic renal cell carcinoma treated by recombinant interleukin-2, recombinant interferon-alpha, 5-fluorouracil, and vinblastine. Cancer Invest. 1999, 17(4): 259-263.
26. Goldsby Richard A, Kindt Thomas J, Osborne Barbara A.原著. Kuby Immunology 免疫學. 許清祥 總校閱. 第四版. 台北. 2002. 合記圖書出版社.
27. Heimdal JH, Aarstad HJ, Klementsen B, Olofsson J. Peripheral blood mononuclear cell (PBMC) responsiveness in patients with head and neck cancer in relation to tumor stage and prognosis. Acta Otolaryngol, 1999, 119:281-284. 28. Hsu HJ, Chang KL, Yang YH, Shieh TY. The Effects Of arecoline on the release of cytokines using peripheral blood mononuclear cells from patients with oral mucous diseases. Kaohsiung J Med Science. 2001, 17:175-183.
29. Lee CH, Ko YC, Huang HL, Chao YY, Tsai CC, Shieh TY, Lin LM. The precancer risk of betel quid chewing, tobacco use and alcohol consumption in oral leukoplakia and oral submucous fibrosis in southern Taiwan. British Journal of Cancer. 2003, 88:366-372.
30. Jefferies S, Eeles R, Goldgar D, A''Hern R, Henk JM, Gore M. The role of genetic factors in predisposition to squamous cell cancer of the head and neck. Br J Cancer. 1999, 79(5-6): 865-867.
31. Jaber MA, Porter SR, Gilthorpe MS, Bedi R, Scully C. Risk factors for oral epithelial dysplasia--the role of smoking and alcohol. Oral Oncol. 1999, 35(2): 151-156.
32. Jaber MA, Porter SR, Scully C, Gilthorpe MS, Bedi R. The role of alcohol in non-smokers and tobacco in non-drinkers in the aetiology of oral epithelial dysplasia. Int J Cancer. 1998, 29; 77(3): 333-336.
33. Joanna Domagala-Kulawik, Grazyna Hoser, Pawel Droszcz, Jerzy Kawiak, Waclaw Droszcz, Ryszarda Chazan. T-cell subsets in bronchoalverlar lavage fluid and in peripheral blood from patients with primary lung cancer. Diagn. Cytopathol. 2001, 25:208-213.
34. John M. In defense of the surgical cancer patient: Nutrition may be key. Bulletin of the American of surgeons. 2001, 86; 1:18-22.
35. Jones Emma, Dahm-Vicker Michaela, Golgher Denise, Gallimore Awen. CD25+ regulatory T cells and tumor immunity. Immunology Letters. 2003, 85:141-143.
36. Jonuleit Helmut, Schmitt Edgar, Kakirman Hacer, Stassen Michael, Knop Jurgen, Enk Alexander H. Infectious tolerance:human CD25+ regulatory T cells convey suppressor activity to conventional CD4+ T helper cells. J Exp Med. 2002, 196(2): 255-260.
37. Kastelan Z, Lukac J, Derezic D, Pasini J, Kusic Z, Sosic H, Kastelan M. Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma. Anticancer Res. 2003, 23(6D): 5185-5189.
38. Kienstra M A, Neel B, Strome S E, Roche P. Indentification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head and neck. 2003, 25:457-463.
39. Koga Chihiro, Itoh Kyogo, Aoki Masatora, Suefuji Yuuichi, Yoshida Minako,Asosina Sumiko, Esaki Kazuhisa, Kameyama Tadamitsu. Anxiety and pain suppress the natural killer cell activity in oral surgery outpatients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001, 91:654-658.
40. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med. 1995, 24:450-453.
41. Kuo HW, Hsiao TY, Lai JS. Immuological effects of long-term lead exposure among Taiwanese workers. Arch Toxicol. 2001, 75:569-573.
42. Kuo HW, Wu ML. Effects of chromic acid exposure on immunological parameters among electroplating workers. Int Arch Occup Environ Health. 2002, 75(3): 186-190.
43. Marion G. Macey. Flow-cytometry Clinical Applications. in Macey MG (ed), Oxford, Blackwell Scientific Publications, London, United Kingdom, pp 67-100, 1994.
44. Marzio R, Mauel J, Betz-Corradin S. CD69 and regulation of the immune function. Immunopharmacol Immunotoxicol. 1999, 21(3): 565-582.
45. McCoY J Philip. Flow cytometry-applications in diagnosic pathology. Clinical laboratory news. 2003, Sep: 8-10.
46. McHugh RS, Shevach EM. The role of suppressor T cells in regulation of immune responses. J Allergy Clin Immunol. 2002, 110(5): 693-702.
47. McHeyzer-Williams M, McHeyzer-Williams L, Panus J, Pogue-Caley R, Bikah G, Driver D, Eisenbraun M. Helper T-cell-regulated B-cell immunity. Microbes Infect. 2003, 5(3): 205-12. Review
48. McMahon Steve, Chen A Y. Head and neck. Cancer and metastasis reviews. 2003, 22:21-24.
49. Melichar B, Touskova M, Solichova D, Kralickova P, Kopecky G. CD4+T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumors. Scand J Chin Lab Invest. 2001, 61(5): 363-370.
50. Melichar B, Touskova M, Dvorak Josef, Jandik P, Kopecky O. The peripheral blood leukocyte phenotype in patients with breast cancer: Effect of doxorubicin/paclitaxel combination chemotherapy. Immunopharmacology and Immunotoxicology. 2001, 23(2): 163-173.
51. Moore BM, Kurago ZB, Fullenkamp CA, Lutz CT. Squamous cell carcinoma cells differentially stimulate NK cell functions: The role of IL-18. Cancer Immunol Immunother. 2003, 52: 107-115.
52. Murta EF, de Andrade JM, Falcao RP, Bighetti S. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori. 2000, 86(5): 403-407.
53. Newman G H, Rees G J, Jones R S, Grove E A, Preece A W. Changes in helper and suppressor T lymphocytes following radiotherapy for breast cancer. Clin Radiol. 1987, 38(2): 191-193.
54. Oschsenbein A F, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, Hemmi S, Hengartner H, Zinkernagel R M. Roles of tumor localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 2001, 411:1058-1064.
55. Pasqualetti D, Ghirardini A, Cafolla M, Biffoni M, Coluzzi S, Vahlio S, Girelli G. Lymphocyte T subsets and natural killer cells in Italian and Philippino blood donors. Vox Sanguinis. 2003, 84: 68-72.
56. Petrini B, Wasserman J, Blomgren H, Glas U. Changes of blood T cell subsets following radiation therapy for breast cancer. Cancer lett. 1983, 19(1): 27-31.
57. Rajentheran R, Mclean NR, Kelly CG, Reed MF, Nolan A. Mailignant transformation of oral lichen planus. Eur J Surgical Oncology. 1999, 25:520-523.
58. Reichert T, DeBruyere M, Deneys V, Totterman T, Lydyard P, Yuksel F, Chapel H, Jewell D, Van Hove L, Linden J, Buchner L. Lymphocyte subset reference ranges
in adult Caucasians. Clin. Immunol Immunopathol. 1991, 60:190-208.
59. Sakaguchi Shimon, Sakaguchi Noriko, Shimizu Jun, Yamazaki Sayuri, Sakihama Toshiko, Itoh Misako, Kuniyasu Yuhshi, Normura Takashi, Toda Masaki, Takahashi Takeshi. Immunologic tolerance maintained by CD4+CD4+ role in
controlling autoimmunity, tumor immunity, and transplantation tolerance.Immunological Reviews. 2001, 182:18-32.
60. Sansoni Paolo, Cossarizza Andrea, Brianti Vincenzo, Fagnoni Francesco.Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood. 1993, 82(9): 2767-2773.
61. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002, 2(6): 389-400.
62. Spencer KR, Ferguson JW, Wiesenfeld D. Current concepts in the management of oral squamous cell carcinoma. Australian Dental Journal. 2002, 47(4): 284-289.
63. Strauss HG, Laban C, Lautenschlager C, Buchmann J, Schneider I, Koelbl H. SCC antigen in the serum as an independent prognostic factor in operable squamous
cell carcinoma of the cervix. Eur J Cancer. 2002, 38:1987-1991.
64. Sturgis E M, Wei Q. Genetic susceptibility-molecular epidemiology of head and neck cancer. Current Opinion in Oncology. 2002, 14:310-317.
65. Testi R, D''Ambrosio D, De Maria R, Santoni A. The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol Today. 1994,15(10): 479-483.
66. Titu LV, Monson John RT, Greenman John. The role of CD8+ T cells in immune responses to colorectal cancer. Cancer Immunol Immuother. 2002, 51:235-247.
67. Timothy J. Yeatman, Nutritional support for the surgical oncology patient. Cancer Control. 2000, 7(6): 563-565.
68. Uppal S S, Verma Shashi, Dhot P S. Normal values of CD4 and CD8 lymphocyte subsets in healthy indian adults and the effects of sex, age, ethnicity, and smoking.
Clin. Cytometry. 2003,52B: 32-36.
69. Van der Pompe G, Autoni M H, Visser A, Heijnen C J. Effect of mild acute stress on immune cell distribution and natural killer cell activity in breast cancer patients.
Biol Psychol. 1998, 48(1): 21-35.
70. Van den Eynde B J, Van der Bruggen P. T cell defined tumor antigens. Current Opinion in Immunology. 1997, 9:684-693.
71. Vidal-Rubio B, Sanchez-Carril M, Oliver-Morales J, Gonzalez-Femandez A, Gambon-Deza F. Changes in human lymphocyte subpopulations in tonsils and
regional lymph nodes of human head and neck squamous carcinoma compared to control lymph nodes. BMC Immunology. 2001, 2(1):2.
72. Visser Karin E de, Schumacher Ton N M, Kruisbeek Ada M. CD8+ T cell tolerance and cancer immunotherapy. Journal of Immunotherapy. 2003, 26(1):1-11.
73. Wei WZ, Morris GP, Kong YC. Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother. 2003, 53(2):73-78.
74. Whiteside Theresa L, Herberman Ronald B. The role of natural killer cells in immune surveillance of cancer. Current Opinion in Immunology, 1995, 7:704-710.
75. Yoshihara Hisashi, Tanaka Noriaki, Orita Kunzo. Suppression of natural killer cell activity by surgical stress in cancer patients and the underlying mechanisms. Acta Med Okayama, 1986, 40(2): 113-119.
76. Ziegler SF, Ramsdell F, Alderson MR. The activation antigen CD69. Stem Cells. 1994, 12(5): 456-465.
77. Ziegler SF, Ramsdell F, Hjerrild K A, Armitage R J, Grabstein K H, Hennen K B, Farrah T, Fanslow W C, Shevach E M, Alderson M R. Molecular charterization of
early activation antigen CD69: a type II membrane glycoprotein related to a family of natural killer cell activation antigens. Eur J Immunol. 1993,
23:1643-1648.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關論文
 
1. 林立樹〈徐光啟〉 載《神學論集》 第91期 1992.04 頁111-117。
2. 劉君燦〈明清實學研究的現況及展望—科技篇〉 載《中國文哲研究通訊》 第2卷第4期
3. 范傳培〈利瑪竇輸入西學的影響〉 載《思與言》 第24卷第2期(「中國科技史研討會」專
4. 洪萬生〈徐光啟〈幾何原本雜義〉雜議〉 載《科學史通訊》 第15期 1997.01 頁28-
5. 林東陽〈有關利瑪竇所著「天主實義」與「畸人十篇」的幾個問題〉 載《大陸雜誌》 第
6. 陳占山,黃定平〈十六至十八世紀入華葡籍耶穌會士述考〉 載《文化雜誌》 第32期
7. 劉兆祐〈論叢書〉 載《應用語文學報》 第1期 1999.06 頁9-20。
8. 梁元生〈求索東西天地間—李之藻由儒入耶的道路〉 載《九州學刊》第3卷第1期
9. 羅華慶〈會通中西哲思的利瑪竇[Matteo Ricci]—《天主實義》評析〉載《文化中國》
10. 錢林森〈利瑪竇[Metteo Ricci]與儒家文化接觸的歷史經驗〉 載《中西文化研究》 第2
11. 劉月蓮〈李卓吾與利西泰—萬曆中西超儒之晤〉 載《文化雜誌》 第43期 2002.夏 頁
12. 蓋瑞忠〈「會通」與「超勝」—試析徐光啟的科技思想〉 載《嘉義師院學報》 第7期
13. 張鳴鐸〈「大秦景教流行中國碑」述略〉 載《中原文獻》 第29卷第3期 1997.07 頁1-
14. 葛榮晉〈明清實學與中國傳統價值觀念的轉變〉 載《哲學雜誌》 第12期 1995.04 頁
15. 黃一農〈明末清初天主教傳華史研究的回顧與展望〉 載《新史學》第7卷第1期 1996.3
 
系統版面圖檔 系統版面圖檔